TABLE 1.
Baseline clinical characteristics of the study population.
| Characteristics | IBD | CD | UC |
| Number of patients | 180 | 128 | 52 |
| Median age (range) | 45 (17–80) | 43 (17–80) | 51 (19–78) |
| Sex (M/F) | 110/70 | 78/50 | 31/20 |
| BMI | 23.78 (14.45–51.0) | 24.07 (14.45–34.30) | 22.95 (16.98–51.0) |
| Montreal Classification | |||
| (CD: L1/L2/L3/L4); UC (E1/E2/E3) | – | 41/10/69/3* | 6/18/26* |
| Clinical activity (mean, 95% CI) (CD: HBI; UC: pMAYO) | – | 6.2 (5.4–7.0) | 3.7 (2.9–4.5) |
| Median Years of illness (range) | 11 (1–49) | 12 (1–49) | 5,5 (2–38) |
| Remission/mild/moderate/severe | 57/47/64/12 | 46/38/40/4 | 11/9/24/8 |
| Previous surgery for IBD (yes/no) | 71/109 | 62/66 | 8/44 |
| Smoke (current/never/former) | 39/75/66 | 32/53/43 | 7/21/24 |
| Biochemical activity | |||
| FC (ug/g) median (95% CI) | 577 (366–872) | 554 (332–872) | 579 (162–1,800) |
| hsCRP (mg/l) median (95% CI) | 6.0 (4.0–7.9) | 5.7 (4.0–7.9) | 6.8 (3.3–12.8) |
| ESR (± /NA) | 71/67/42 | 52/49/27 | 14/21/17 |
| Systemic corticosteroids (yes/no) | 74/106 (41.1%) | 49/79 (38.2%) | 27/25 (51.9%) |
*For some patients (5 for CD and 2 for UC) the Montreal classification was not available.